Our Network Voydeya (danicopan) granted first-ever regulatory approval in Japan for adults with PNH to be used in combination with C5 inhibitor therapy Tags: #Research #Clinical research #PNH #AstraZeneca #Rare disease Approval of first-in-class, oral, Factor D inhibitor based on ALPHA Phase III trial in a subset of patients with PNH.
